Table 4.
The main pharmacokinetic parameters of enasidenib (n = 6, mean ± SD).
| Parameters | Group A | Group B |
|---|---|---|
| t 1/2 (h) | 7.74 ± 0.91 | 8.64 ± 0.42 |
| T max (h) | 1.33 ± 0.41 | 2.50 ± 0.55∗∗ |
| C max (ng/mL) | 458.87 ± 136.02 | 661.47 ± 107.32∗ |
| CLz/F (L/h/kg) | 2.70 ± 1.13 | 1.79 ± 0.35∗∗ |
| V z/F (L/h) | 30.52 ± 15.33 | 22.23 ± 3.88∗ |
| MRT(0 − t) (h) | 11.10 ± 1.03 | 11.01 ± 0.88 |
| MRT(0 − ∞) (h/) | 11.78 ± 0.99 | 11.97 ± 1.07∗ |
| AUC(0 − t) (ng·h/mL) | 4067.24 ± 1214.36 | 5645.40 ± 1046.30∗ |
| AUC(0 − ∞) (ng·h/mL) | 4125.79 ± 1235.91 | 5759.61 ± 1078.59 |
Abbreviations: t1/2: half-life; Tmax: time of peak concentration; MRT(0 − t): mean residence time of 0 − t time; MRT(0 − −∞): mean residence time of 0-infinity time; Cmax: peak concentration; AUC(0 − t): area under curve of 0 − t time; AUC(0 − ∞): area under curve of 0-infinity time. (Compared with the Group A, ∗P < 0.05; ∗∗P < 0.01).